US2021388071A1PendingUtilityA1

Antibodies against human angiopoietin 2

78
Assignee: HOFFMANN LA ROCHEPriority: Dec 16, 2008Filed: Apr 5, 2021Published: Dec 16, 2021
Est. expiryDec 16, 2028(~2.4 yrs left)· nominal 20-yr term from priority
Inventors:Ulrich BrinkmannRemko Albert GriepKlaus KaluzaAnita KavlieChristian KleinJoerg Thomas RegulaWerner Scheuer
A61K 39/00C07K 2317/73A61P 9/10C07K 2317/21C07K 2317/56C07K 16/22C12N 15/85A61P 9/00A61K 2039/505C12N 15/11A61P 7/00C07K 2317/565C07K 2317/76A61P 35/04A61P 35/00A61K 39/395A61P 27/02C07K 2317/92
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody that specifically binds to human angiopoietin-2 (ANG-2), wherein the antibody binds to the same epitope as an antibody comprising:
 (A) a heavy chain variable domain which comprises a CDR3 region having the sequence of SEQ ID NO: 33, a CDR2 region having the sequence of SEQ ID NO: 34 and a CDR1 region having the sequence of SEQ ID NO: 35; and   (B) a light chain variable domain which comprises a CDR3 region having the sequence of SEQ ID NO: 36, a CDR2 region having the sequence of SEQ ID NO: 37 and a CDR1 region having the sequence of SEQ ID NO: 38.   
     
     
         2 . The antibody of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody is a human IgG4 antibody or a human IgG1 antibody. 
     
     
         4 . A pharmaceutical formulation comprising the antibody of any one of  claims 1  to  3 . 
     
     
         5 . An isolated antibody that specifically binds to human ANG-2, wherein the antibody binds to the same epitope as an antibody comprising a heavy chain comprising SEQ ID NO: 39 and a light chain comprising SEQ ID NO: 40. 
     
     
         6 . The antibody of  claim 5 , wherein the antibody is a monoclonal antibody. 
     
     
         7 . The antibody of  claim 5 , wherein the antibody is a human IgG4 antibody or a human IgG1 antibody. 
     
     
         8 . A pharmaceutical formulation comprising the antibody of any one of  claims 5  to  7 .

Join the waitlist — get patent alerts

Track US2021388071A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.